Existence and Significance of Anti-HLA-C Autoantibodies to Primary and Persistent Platelet Transfusion Refractoriness in Patients with Hematologic Disorders: a Retrospective Study from a Single Centre

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Dec 28

PMID 39731480

Authors

Xunhua Li

Qi Liu

Jingjie Dong

Yaonan Hong

Chuanao Xin

Junfeng Guo

Shan Liu

Peicheng Wang

Zexing Sun

Yingying Shen

Xiawan Yang

Hangchao Li

Yiping Shen

Jianping Shen

Baodong Ye

Yuhong Zhou

Tonglin Hu

Dijiong Wu

Affiliations

Soon will be listed here.

Abstract

Objectives: Platelet transfusion refractoriness (PTR) is a frustrating clinical problem, and primary and persistent (P/P) PTR who experienced persistent PTR since the first transfusion was failed to be well recognized. This study aims to investigate the incidence and risk factors for P/P PTR.

Methods: Patients with hematologic disorders who underwent HLA high-resolution genotyping and donor-specific HLA antibody or panel reactive antibody (PRA) testing between January 2019 and March 2023 were reviewed. Clinical data including infection history, splenomegaly, frequency and quantity of blood transfusions, and transfusions response were delineated and subsequently analyzed.

Results: 114 patients were included retrospectively, and 1071 transfusions were recorded. The overall incidence of PTR was 28.95% (33/114), with 63.63% (21/33) being P/P PTR. Anti class I HLA (anti-HLA-I) antibody was identified as an independent risk factor for ineffective platelet transfusion through multivariate logistic regression analysis ( = .034). Interestingly, anti-HLA-C autoantibodies were first found in six patients, and both anti-HLA-A and C autoantibodies were detected in one case, comprising a total of 10.71% (6/56) of HLA-I antibody-positive patients. Further analysis revealed that anti-HLA-C autoantibody was identified as an independent risk factor for P/P PTR ( = .039). Among patients with positive anti-HLA-C antibodies, significant differences in the effectiveness of ABO, D-matched and cross-matching transfusions were observed between patients with or without anti-HLA-C autoantibodies ( < .001 and = .017). Notably, platelet transfusions independence was achieved by two of the four patients who received rituximab.

Conclusions: This work emphasized the significance of anti-HLA-C autoantibody for P/P PTR in hematological patients, and rituximab may therapeutic.

References

Forest S, Hod E . Management of the Platelet Refractory Patient. Hematol Oncol Clin North Am. 2016; 30(3):665-77. DOI: 10.1016/j.hoc.2016.01.008. View

Toor A, Choo S, Little J . Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000; 26(3):315-20. DOI: 10.1038/sj.bmt.1702490. View

Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas F . A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation. Haematologica. 2018; 103(10):1741-1752. PMC: 6165798. DOI: 10.3324/haematol.2018.189365. View

Song X, Qi J, Li X, Zhou M, He J, Chu T . Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases. Platelets. 2023; 34(1):2229905. DOI: 10.1080/09537104.2023.2229905. View

Moncharmont P . Platelet component transfusion and alloimmunization: Where do we stand?. Transfus Clin Biol. 2018; 25(3):172-178. DOI: 10.1016/j.tracli.2018.01.003. View

Solves P, Sanz J, Freiria C, Santiago M, Villalba A, Gomez I . Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017; 97(1):161-167. DOI: 10.1007/s00277-017-3168-6. View

Rijkers M, Schmidt D, Lu N, Kramer C, Heidt S, Mulder A . Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets. Haematologica. 2018; 104(2):403-416. PMC: 6355480. DOI: 10.3324/haematol.2018.201665. View

Kickler T, Kennedy S, Braine H . Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion. 1990; 30(7):622-5. DOI: 10.1046/j.1537-2995.1990.30790385520.x. View

. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1998; 337(26):1861-9. DOI: 10.1056/NEJM199712253372601. View

10.

Gao X, Kou L, Tian H, Wang X . [Correlative Analysis between Production of Platelet HLA-Ⅰ Antibody and HLA-A, B Genes in Patients with Malignant Hematological Diseases]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022; 30(4):1203-1207. DOI: 10.19746/j.cnki.issn.1009-2137.2022.04.036. View

11.

Hod E, Schwartz J . Platelet transfusion refractoriness. Br J Haematol. 2008; 142(3):348-60. DOI: 10.1111/j.1365-2141.2008.07189.x. View

12.

Wong M, Narra R, Selim M, Zimmerman M, Kim J, Padmanabhan A . Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. J Surg Res. 2020; 255:99-105. DOI: 10.1016/j.jss.2020.05.029. View

13.

Liu W, Wu D, Hu T, Ye B . Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases. Int J Clin Exp Med. 2015; 8(8):14080-4. PMC: 4613057. View

14.

Fu Q, Xu L, Zhang X, Wang Y, Chang Y, Liu K . Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. Sci China Life Sci. 2017; 61(5):569-577. DOI: 10.1007/s11427-017-9110-0. View

15.

Kerkhoffs J, Eikenboom J, van de Watering L, van Wordragen-Vlaswinkel R, Wijermans P, Brand A . The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008; 48(9):1959-65. DOI: 10.1111/j.1537-2995.2008.01799.x. View

16.

Frischknecht L, Deng Y, Wehmeier C, de Rougemont O, Villard J, Ferrari-Lacraz S . The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation - Data from the Swiss transplant cohort study. Front Immunol. 2022; 13:1005790. PMC: 9532952. DOI: 10.3389/fimmu.2022.1005790. View

17.

Schiffer C, Anderson K, Bennett C, Bernstein S, Elting L, Goldsmith M . Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19(5):1519-38. DOI: 10.1200/JCO.2001.19.5.1519. View

18.

Yu Q, Shen Y, Ye B, Zhou Y . Successful use of rituximab in platelet transfusion refractoriness in a multi-transfused patient with myelodysplastic syndrome. Platelets. 2013; 26(2):195-6. DOI: 10.3109/09537104.2013.789842. View

19.

Blandin L, Douge A, Fayard A, Bay J, Berlie G, Pereira B . Platelet transfusion refractoriness and anti-HLA immunization. Transfusion. 2021; 61(6):1700-1704. DOI: 10.1111/trf.16358. View

20.

Okubo M, Nishida E, Watanabe A, Nishizaki N, Obinata K, Azuma F . Marked thrombocytopenia in a neonate is associated with anti-HPA-5b, anti-HLA-A31, and anti-HLA-B55 antibodies. Pediatr Blood Cancer. 2018; 66(3):e27555. DOI: 10.1002/pbc.27555. View